Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: Systematic literature review and meta-analysis

European Journal of Health Economics

Volumn 15, Issue SUPPL. 1, 2014, Pages

  Baji, Petra ^a   Péntek, Márta ^a,b   Szántó, Sándor ^c   Géher, Pál ^d   Gulácsi, László ^a   Balogh, Orsolya ^a   Brodszky, Valentin ^a  

^a Institute of Entrepreneurship and Innovation   (Hungary)

^b Pest Megyei Flor Ferenc Korhaz   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d Budai Irgalmasrendi Hospital   (Hungary)

Author keywords

Ankylosing spondylitis; Biological drug; Biosimilar pharmaceuticals; Efficacy; Meta analysis; Safety

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; CTP 13; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INFLIXIMAB BIOSIMILAR; PLACEBO; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL SOCIETY; META ANALYSIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; COMPARATIVE STUDY; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84905709431     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0593-5     Document Type: Article

References (32)

1. Péntek, M., Poór, Gy., Wiland, P., Martina, O., Brzosko, M., Codrenau, C., Brodszky, N., Gulácsi, L.: Biologic therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur. J. Health Econ. (2014). doi:10.1007/s10198-014-0592-6
2. Park, W., Hrycaj, P., Jeka, S., Kovalenko, V., Lysenko, G., Miranda, P., Mikazane, H., Gutierrez-Urena, S., Lim, M., Lee, Y.A., Lee, S.J., Kim, H., Yoo, D.H., Braun, J.: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72(10), 1605-1612 (2013)
3. Sieper, J., Rudwaleit, M., Baraliakos, X., Brandt, J., Braun, J., Burgos-Vargas, R., Dougados, M., Hermann, K.G., Landewe, R., Maksymowych, W., van der Heijde, D.: The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann. Rheum. Dis. 68(Suppl 2), ii1-ii44 (2009)
4. Migliore, A., Broccoli, S., Bizzi, E., Lagana, B.: Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials. J. Med. Econ. 15(3), 473-480 (2012)
5. Ades, A.E., Sculpher, M., Sutton, A., Abrams, K., Cooper, N., Welton, N., Lu, G.: Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 24(1), 1-19 (2006)
6. Lu, G., Ades, A.E.: Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105-3124 (2004)
7. Higgins, J.P.T., Green, S.: Cochrane handbook for systematic reviews of interventions version 5.0.2 [updated September 2009]. The Cochrane Collaboration (2009)
8. McLeod, C., Bagust, A., Boland, A., Dagenais, P., Dickson, R., Dundar, Y., Hill, R.A., Jones, A., Mujica Mota, R., Walley, T.: Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol. Assess. 11(28), 1-158 (iii-iv) (2007)
9. van der Linden, S., Valkenburg, H.A., Cats, A.: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27(4), 361-368 (1984)
10. Baji, P., Péntek, M., Czirják, L., Szekanecz, Z., Nagy, Gy., Gulácsi, L., Brodszky, V.: Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis; a mixed treatment comparison. Eur. J. Health Econ. Suppl. (2014). doi:10.1007/s10198-014-0594-4
11. Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., McQuay, H.J.: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1), 1-12 (1996)
12. Huang, F., Gu, J., Zhu, P., Bao, C., Xu, J., Xu, H., Wu, H., Wang, G., Shi, Q., Andhivarothai, N., Anderson, J., Pangan, A.L.: Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann. Rheum. Dis. 73(3), 587-594 (2014)
13. van der Heijde, D., Da Silva, J.C., Dougados, M., Geher, P., van der Horst-Bruinsma, I., Juanola, X., Olivieri, I., Raeman, F., Settas, L., Sieper, J., Szechinski, J., Walker, D., Boussuge, M.P., Wajdula, J.S., Paolozzi, L., Fatenejad, S.: Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann. Rheum. Dis. 65(12), 1572-1577 (2006)
14. Barkham, N., Coates, L.C., Keen, H., Hensor, E., Fraser, A., Redmond, A., Cawkwell, L., Emery, P.: Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis.Ann.Rheum. Dis. 69(11), 1926-1928 (2010)
15. Dougados, M., Braun, J., Szanto, S., Combe, B., Elbaz, M., Geher, P., Thabut, G., Leblanc, V., Logeart, I.: Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann. Rheum. Dis. 70(5), 799-804 (2011)
16. Inman, R.D., Davis Jr, J.C., Heijde, D., Diekman, L., Sieper, J., Kim, S.I., Mack, M., Han, J., Visvanathan, S., Xu, Z., Hsu, B., Beutler, A., Braun, J.: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58(11), 3402-3412 (2008)
17. Inman, R.D., Maksymowych, W.P.: A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J. Rheumatol. 37(6), 1203-1210 (2010)
18. Marzo-Ortega, H., McGonagle, D., Jarrett, S., Haugeberg, G., Hensor, E., O'Connor, P., Tan, A.L., Conaghan, P.G., Greenstein, A., Emery, P.: Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann. Rheum. Dis. 64(11), 1568-1575 (2005)
19. van der Heijde, D., Kivitz, A., Schiff, M.H., Sieper, J., Dijkmans, B.A., Braun, J., Dougados, M., Reveille, J.D., Wong, R.L., Kupper, H., Davis Jr, J.C.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54(7), 2136-2146 (2006)
20. Maksymowych, W., Rahman, P., Keystone, E., Wong, R.L., Inman, R.: Efficacy of adalimumab in active ankylosing spondylitis (AS) - results of the Canadian AS study. Arthritis Rheum. 52, 505 (2005)
21. Gorman, J.D., Sack, K.E., Davis Jr, J.C.: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 346(18), 1349-1356 (2002)
22. Calin, A., Dijkmans, B.A., Emery, P., Hakala, M., Kalden, J., Leirisalo-Repo, M., Mola, E.M., Salvarani, C., Sanmarti, R., Sany, J., Sibilia, J., Sieper, J., van der Linden, S., Veys, E., Appel, A.M., Fatenejad, S.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis. 63(12), 1594-1600 (2004)
23. Davis Jr, J.C., Van Der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D.O., Kivitz, A., Fleischmann, R., Inman, R., Tsuji, W.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48(11), 3230-3236 (2003)
24. Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-Ihle, E., Kellner, H., Krause, A., Schneider, M., Sorensen, H., Zeidler, H., Thriene, W., Sieper, J.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313), 1187-1193 (2002)
25. van der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., De-Woody, K., Williamson, P., Braun, J.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52(2), 582-591 (2005)
26. Brandt, J., Khariouzov, A., Listing, J., Haibel, H., Sorensen, H., Grassnickel, L., Rudwaleit, M., Sieper, J., Braun, J.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 48(6), 1667-1675 (2003)
27. Boyce, E.G., Halilovic, J., Stan-Ugbene, O.: Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. Clin. Ther. 32(10), 1681-1703 (2010)
28. Poddubnyy, D., Rudwaleit, M.: Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Expert Opin. Drug Saf. 10(4), 655-673 (2011)
29. Li, Z.H., Zhang, Y., Wang, J., Shi, Z.J.: Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur. J. Orthop. Surg. Traumatol. 23(5), 497-506 (2013)
30. Thaler, K.J., Gartlehner, G., Kien, C., Van Noord, M.G., Thakurta, S., Wines, R.C.M., Hansen, R.A., McDonagh, M.S.: Drug class review: targeted immune modulators: final update 3 report [Internet]. http://pharmacy.oregonstate.edu/ drug-policy/sites/default/files/pages/dur-board/reviews/articles/ 2012-06-28-TIMS-executive.pdf (2012)
31. Shu, T., Chen, G.H., Rong, L., Feng, F., Yang, B., Chen, R., Wang, J.: Indirect comparison of anti-TNF-alpha agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials. Clin. Exp. Rheumatol. 31(5), 717-722 (2013)
32. Zochling, J.: Measures of symptoms and disease status in ankylosing spondylitis: ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken) 63(Suppl 11), S47-S58 (2011)